CN112424189A - 吡咯烷基脲衍生物及其在TrkA相关疾病的应用 - Google Patents

吡咯烷基脲衍生物及其在TrkA相关疾病的应用 Download PDF

Info

Publication number
CN112424189A
CN112424189A CN201980046866.7A CN201980046866A CN112424189A CN 112424189 A CN112424189 A CN 112424189A CN 201980046866 A CN201980046866 A CN 201980046866A CN 112424189 A CN112424189 A CN 112424189A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
isomer
acceptable salt
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980046866.7A
Other languages
English (en)
Other versions
CN112424189B (zh
Inventor
张杨
伍文韬
李志祥
秦健
李婕
龚珍
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Original Assignee
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhangzhou Pientzehuang Pharmaceutical Co Ltd filed Critical Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Publication of CN112424189A publication Critical patent/CN112424189A/zh
Application granted granted Critical
Publication of CN112424189B publication Critical patent/CN112424189B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Abstract

本发明涉及一类TrkA抑制剂，及其在制备治疗与TrkA相关疾病的药物中的应用。具体公开了式(Ⅰ)和式(Ⅱ)所示化合物、其互变异构体或其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (20)

  1. PCT国内申请，权利要求书已公开。
CN201980046866.7A 2018-07-12 2019-07-11 吡咯烷基脲衍生物及其在TrkA相关疾病的应用 Active CN112424189B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201810761702 2018-07-12
CN201810761702X 2018-07-12
CN2018113075822 2018-11-05
CN201811307582 2018-11-05
PCT/CN2019/095576 WO2020011227A1 (zh) 2018-07-12 2019-07-11 吡咯烷基脲衍生物及其在TrkA相关疾病的应用

Publications (2)

Publication Number Publication Date
CN112424189A true CN112424189A (zh) 2021-02-26
CN112424189B CN112424189B (zh) 2023-07-07

Family

ID=69142096

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980046866.7A Active CN112424189B (zh) 2018-07-12 2019-07-11 吡咯烷基脲衍生物及其在TrkA相关疾病的应用

Country Status (5)

Country Link
US (1) US11932652B2 (zh)
EP (1) EP3822266A4 (zh)
JP (1) JP7083436B2 (zh)
CN (1) CN112424189B (zh)
WO (1) WO2020011227A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4089086A4 (en) * 2020-01-10 2023-07-05 Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. CRYSTAL FORM OF PYRROLIDINYLUREA DERIVATIVE AND ITS USE
EP4089087A4 (en) * 2020-01-10 2023-06-14 Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. METHOD FOR PREPARING A PYRROLIDINYL-UREA DERIVATIVE

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103649076A (zh) * 2011-05-13 2014-03-19 阵列生物制药公司 作为trka激酶抑制剂的吡咯烷基脲和吡咯烷基硫脲化合物
WO2017135399A1 (ja) * 2016-02-04 2017-08-10 塩野義製薬株式会社 ＴｒｋＡ阻害活性を有する含窒素複素環および炭素環誘導体
US20170240512A1 (en) * 2014-08-06 2017-08-24 Shionogi & Co., Ltd. Heterocycle and carbocycle derivatives having trka inhibitory activity
CN107531589A (zh) * 2015-01-23 2018-01-02 Gvk生物科技私人有限公司 TrkA激酶抑制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104781255B (zh) 2012-11-13 2017-10-24 阵列生物制药公司 作为trka激酶抑制剂的n‑吡咯烷基、n’‑吡唑基‑脲、硫脲、胍和氰基胍化合物
CR20160583A (es) 2014-05-15 2017-02-23 Array Biopharma Inc 1-((3s,4r)-4-(3-fluorofenil)-1-(2-metoxietil)pirrolidin-3-il)-3-(4-metil-3-(2-metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)urea como inhibidor de trka cinasa
WO2017006953A1 (ja) 2015-07-07 2017-01-12 塩野義製薬株式会社 ＴｒｋＡ阻害活性を有する複素環誘導体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103649076A (zh) * 2011-05-13 2014-03-19 阵列生物制药公司 作为trka激酶抑制剂的吡咯烷基脲和吡咯烷基硫脲化合物
US20170240512A1 (en) * 2014-08-06 2017-08-24 Shionogi & Co., Ltd. Heterocycle and carbocycle derivatives having trka inhibitory activity
CN107531589A (zh) * 2015-01-23 2018-01-02 Gvk生物科技私人有限公司 TrkA激酶抑制剂
WO2017135399A1 (ja) * 2016-02-04 2017-08-10 塩野義製薬株式会社 ＴｒｋＡ阻害活性を有する含窒素複素環および炭素環誘導体

Also Published As

Publication number Publication date
WO2020011227A1 (zh) 2020-01-16
CN112424189B (zh) 2023-07-07
EP3822266A4 (en) 2022-04-27
JP7083436B2 (ja) 2022-06-13
JP2021530496A (ja) 2021-11-11
US11932652B2 (en) 2024-03-19
US20210147436A1 (en) 2021-05-20
EP3822266A1 (en) 2021-05-19

Similar Documents

Publication Publication Date Title
CN109310675A (zh) 治疗性抑制化合物
JP2014530203A (ja) ヤヌスキナーゼ阻害剤としてのシアノメチルピラゾールカルボキサミド
CN112689638B (zh) 作为lsd1抑制剂的环丙胺类化合物及其应用
JP7168149B2 (ja) Ｆｇｆｒ阻害剤としてのピラジン－２（１ｈ）－オン系化合物
TWI793999B (zh) 嘧啶並吡喃化合物
CN112566907A (zh) 作为ret抑制剂的吡唑衍生物
CN112424189B (zh) 吡咯烷基脲衍生物及其在TrkA相关疾病的应用
CN114502561A (zh) Lsd1抑制剂
CN111148515B (zh) 2,6-二氧杂螺[4,5]癸烷类衍生物、其制备方法及其在医药上的应用
TW202317097A (zh) 戊二醯亞胺類化合物與其應用
TW202237597A (zh) 新型egfr降解劑
TW202231633A (zh) Cdk抑制劑
CN113874379B (zh) 作为Cdc7抑制剂的四并环类化合物
CN114008046B (zh) 作为cdk9抑制剂的氮杂吲哚连吡唑类化合物
KR20230043955A (ko) 키나아제 억제 활성을 갖는 화합물
RU2771201C2 (ru) ПИРИДОПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ, ВЫПОЛНЯЮЩИЕ ФУНКЦИЮ ДВОЙНЫХ ИНГИБИТОРОВ mTORC 1/2
WO2020094084A1 (zh) 作为ret抑制剂的三并环衍生物
WO2022166721A1 (zh) 含1，4-氧杂氮杂环庚烷的并环类衍生物
TW202322812A (zh) 吡唑［３，４－ｄ］嘧啶－３－酮類化合物、包含其的藥物組合物及其醫藥用途
JP2023539275A (ja) 新規なｒｈｏ関連タンパク質キナーゼ阻害剤の調製方法およびその調製方法における中間体
CN113286594B (zh) 吡啶并嘧啶类化合物在制备治疗鼻咽癌药物中的应用
CN116888108B (zh) 新型egfr降解剂
CN107614501A (zh) 羟基嘌呤类化合物及其应用
WO2023001282A1 (zh) 杂环取代的嘧啶衍生物
TW202346306A (zh) 橋環取代的雜芳基並吡喃類衍生物及其應用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: 363000 No. 1, Amber Road, Xiangcheng District, Zhangzhou City, Fujian Province

Applicant after: ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL Co.,Ltd.

Address before: 363000, Fujian, Zhangzhou streets

Applicant before: ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL Co.,Ltd.

GR01 Patent grant
GR01 Patent grant